Partnering with entrepreneurs to create platforms that transform healthcare
L1 Health is looking to develop industry leading platforms that transform healthcare. We partner with entrepreneurs and industry executives to identify and invest in creative ideas that take advantage of powerful, long-term global trends and have the potential to change healthcare and improve lives. We understand the time and operational focus required to achieve success. With over $3bn in evergreen capital, L1 Health can dedicate the time it takes to build industry leaders, invest throughout the economic cycle, and tailor its approach to each opportunity – from minority stakes to majority control, from start-up companies to industry leaders.
'The macro challenges of 2020 have validated our approach of investing in long-term trends and transformative platforms'
Our year in review
Looking back on a year of resilience, ingenuity and achievement.Our year in review - L1 Health
Net assets under management (31 Dec 2021)
The L1 Health team
In October 2019 L1 Health acquired Destination Pet and launched a new animal health and wellness platform in the US and Europe. Destination Pet is a leader in pet health care services and a trusted high-quality pet care and vet services provider.
Formed in 2019, K2 HealthVentures (K2HV) is a start-up venture, providing life sciences companies at the venture and growth stages with innovative financing solutions.
In October 2021, through the consensual restructuring agreement achieved with Ascendis Health Ltd. Shareholders, L1 Health acquired Remedica Ltd. in a joint venture with Blantyre Capital. Founded in 1980, Remedica is a leading pharmaceutical company in Cyprus, specialized in the development, manufacturing and sale of both complex and essential branded generics.
LetterOne is a partnership of successful entrepreneurs and international business people.Home
As active investors we work closely with founders and management teams to realise their company's potential.About us
L1 is built on the expertise of our people – from our executive, to our investment teams and world-class advisory board members.Our people